TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients With Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Rociletinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms TIGER-2
- Sponsors Clovis Oncology [CEASED]
- 28 Jul 2020 Number of arms changed from 1 to 3. Experimental atms: Rociletinib Mono-Therapy, T790M +ve (500mg BID) and Rociletinib Mono-Therapy, T790M -ve (500mg BID) added to study protocol. Study allocation changed to Randomized.
- 30 Sep 2019 Status changed from active, no longer recruiting to discontinued.
- 07 Sep 2018 Planned primary completion date changed from 1 Dec 2016 to 31 Aug 2019.